AIM ImmunoTech expects Q1 2027 topline data from Phase 2 DURIPANC trial of Ampligen plus durvalumab in metastatic pancreatic cancer

Bitget2026/09/30 12:44

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

AIM ImmunoTech highlighted its ongoing Phase 2 DURIPANC study testing Ampligen with AstraZeneca’s durvalumab in metastatic pancreatic cancer.
Topline results have not been presented yet; the company expects them in Q1 2027, with overall survival analysis starting in Q3 2027.
An earlier named-patient experience suggested longer survival for selected patients receiving Ampligen as maintenance, supporting further randomized testing.
The company framed neutrophil-to-lymphocyte ratio as a potential tool to select patients more likely to benefit, pending confirmation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AIM ImmunoTech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609300844PRIMZONEFULLFEED9836508) on September 30, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

AIM ImmunoTech expects Q1 2027 topline data from Phase 2 DURIPANC trial of Ampligen plus durvalumab in metastatic pancreatic cancer

You may also like

Crypto prices